Report Code : CVMI2603252601422 | Published Date : March 30, 2025

1 | Market Overview
The global checkpoint inhibitors market is experiencing rapid growth, fueled by the increasing prevalence of cancer and rising demand for immunotherapy treatments. Checkpoint inhibitors work by blocking immune checkpoints such as PD-1, PD-L1, and CTLA-4, thus enabling the immune system to attack cancer cells more effectively.

The expansion of the checkpoint inhibitors market is driven by rising approvals of new indications, growing oncology research, and ongoing investment in combination therapies. Advances in biomarker-driven patient selection and precision medicine are additionally accelerating the market's growth.

 

2 | Market Size and Forecast

Year

Market Value (USD Billion)

Notes

2019

23.5

Historical benchmark

2024

41.9

Five-year CAGR 12.1%

2031

98.6

Seven-year CAGR 12.9%

The market is projected to more than double by 2031, propelled by wider cancer indication approvals and increased adoption of immunotherapies globally.

 

3 | Key Market Drivers

  • Rising Cancer Incidence Worldwide.
  • Increased Adoption of Immunotherapy as First-Line Treatment.
  • Expanding Pipeline for Multiple Cancer Types.
  • Biomarker-Driven Patient Selection and Precision Medicine.
  • Favorable Regulatory Approvals for New Indications.

 

4 | Market Challenges

  • High Treatment Costs.
  • Immune-Related Adverse Events (irAEs).
  • Variable Response Rates Among Patients.
  • Regulatory Complexities in Emerging Markets.

 

5 | Competitive Landscape
The checkpoint inhibitors market is highly consolidated, dominated by leading pharmaceutical companies with blockbuster oncology drugs.

Market Share Estimates (2024):

Company

Estimated Market Share

Key Products

Bristol-Myers Squibb

24%

Opdivo® (nivolumab), Yervoy® (ipilimumab)

Merck & Co.

21%

Keytruda® (pembrolizumab)

Roche (Genentech)

16%

Tecentriq® (atezolizumab)

AstraZeneca

12%

Imfinzi® (durvalumab)

Others (Pfizer, Novartis, Gilead, BeiGene)

27%

Novel and regional checkpoint inhibitors

 

6 | Market Segmentation
By Drug Class:

  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4 Inhibitors
  • Others (LAG-3, TIGIT, emerging targets)

 

By Application:

  • Lung Cancer
  • Melanoma
  • Renal Cell Carcinoma
  • Bladder Cancer
  • Head and Neck Cancer
  • Others (Triple-Negative Breast Cancer, Gastrointestinal Cancers)

 

By End User:

  • Hospitals
  • Oncology Centers
  • Research Institutes
  • Specialty Clinics

 

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

 

7 | Strategic Outlook
The checkpoint inhibitors market will continue evolving with next-generation checkpoint targets (e.g., LAG-3, TIM-3, TIGIT), biomarker-driven treatments, AI-powered drug discovery, and expansion into early-stage cancers and adjuvant therapy settings.





Reasons To Buy

Image



Scope

Image

Key Players

  • Bristol Myers Squibb
  • Merck & Co.
  • Roche
  • AstraZeneca
  • Pfizer
  • Novartis
  • Regeneron
  • Gilead Sciences

 

Global Checkpoint Inhibitors Market Report

  

  1. 1. Global Checkpoint Inhibitors Market Research Report
    1. 1.1 Study Objectives
    2. 1.2 Global Checkpoint Inhibitors Market - Overview
    3. 1.3 Reason to Read This Report
    4. 1.4 Methodology and Forecast Analysis
  2. 2. Global Checkpoint Inhibitors Market Research Report - Preface
    1. 2.1 Global Checkpoint Inhibitors Market Research Report – Detailed Scope and Definitions
      1. 2.1.1 By Drug Class
      2. 2.1.2 By Application
      3. 2.1.3 By End User
      4. 2.1.4 By Region
  3. 3. Global Checkpoint Inhibitors Market Dynamics
    1. 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
    2. 3.2. Restraints – By Drug Class, By Application, By End User, By Country
    3. 3.3. Opportunities – By Drug Class, By Application, By End User, By Country
    4. 3.4. Trends – By Drug Class, By Application, By End User, By Country
    5. 3.5. PEST Analysis
    6. 3.6. Porters Five Rule Analysis
    7. 3.7. Company’s Share Analysis (CSA) by Region or By Country
    8. 3.8. Global Checkpoint Inhibitors Market Research Report – DROTs Impact Analysis
    1. 4. Global Checkpoint Inhibitors Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
    2. 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
    4. 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
    5. 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 5. Global Checkpoint Inhibitors Market, By Drug Class, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 5.1 PD-1 Inhibitors
    2. 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 5.2 PD-L1 Inhibitors
    7. 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 5.3 CTLA-4 Inhibitors
    12. 5.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 5.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 5.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 5.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    16. 5.4 Others (LAG-3, TIGIT, emerging targets)
    17. 5.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    18. 5.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    19. 5.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    20. 5.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. Global Checkpoint Inhibitors Market, By Application, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 6.1 Lung Cancer
    2. 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 6.2 Melanoma
    7. 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 6.3 Renal Cell Carcinoma
    12. 6.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 6.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 6.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 6.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    16. 6.4 Bladder Cancer
    17. 6.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    18. 6.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    19. 6.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    20. 6.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    21. 6.5 Head and Neck Cancer
    22. 6.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    23. 6.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    24. 6.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    25. 6.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    26. 6.6 Others (Triple-Negative Breast Cancer, Gastrointestinal Cancers)
    27. 6.6.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    28. 6.6.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    29. 6.6.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    30. 6.6.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    7. Global Checkpoint Inhibitors Market, By End User, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 7.1 Hospitals
    2. 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 7.2 Oncology Centers
    7. 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 7.3 Research Institutes
    12. 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    16. 7.4 Specialty Clinics
    17. 7.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    18. 7.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    19. 7.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    20. 7.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 8. Global Checkpoint Inhibitors Market Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
    1. 8.1 North America
      1. 8.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      8.2 Europe
      1. 8.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      8.3 Asia-Pacific
      1. 8.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      8.4 Latin America
      1. 8.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      8.5 Middle East and Africa
      1. 8.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      8.6 Global Checkpoint Inhibitors Market - Opportunity Analysis Index, By Drug Class, By Application, By End User, and Region, 2024 - 2031
  1. 9. North America Global Checkpoint Inhibitors Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 9.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.1.1 PD-1 Inhibitors
      2. 9.1.2 PD-L1 Inhibitors
      3. 9.1.3 CTLA-4 Inhibitors
      4. 9.1.4 Others (LAG-3, TIGIT, emerging targets)
      9.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.2.1 Lung Cancer
      2. 9.2.2 Melanoma
      3. 9.2.3 Renal Cell Carcinoma
      4. 9.2.4 Bladder Cancer
      5. 9.2.5 Head and Neck Cancer
      6. 9.2.6 Others (Triple-Negative Breast Cancer, Gastrointestinal Cancers)
      9.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.3.1 Hospitals
      2. 9.3.2 Oncology Centers
      3. 9.3.3 Research Institutes
      4. 9.3.4 Specialty Clinics
      9.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.4.1 United States
      2. 9.4.2 Canada
    2. 9.5 North America Global Checkpoint Inhibitors Market – Opportunity Analysis Index, By Drug Class, By Application, By End User, and Country, 2024 - 2031
    3. 9.6 Regional Trends Analysis
    4. 9.7 North America Global Checkpoint Inhibitors Market Research Report - Company Profiles
      1. 9.7.1 Company 1 (United States)
      2. 9.7.2 Company 2 (Canada)
      3. 9.7.3 Company 3 (Canada)
    10. Europe Global Checkpoint Inhibitors Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 10.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.1.1 PD-1 Inhibitors
      2. 10.1.2 PD-L1 Inhibitors
      3. 10.1.3 CTLA-4 Inhibitors
      4. 10.1.4 Others (LAG-3, TIGIT, emerging targets)
      10.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.2.1 Lung Cancer
      2. 10.2.2 Melanoma
      3. 10.2.3 Renal Cell Carcinoma
      4. 10.2.4 Bladder Cancer
      5. 10.2.5 Head and Neck Cancer
      6. 10.2.6 Others (Triple-Negative Breast Cancer, Gastrointestinal Cancers)
      10.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.3.1 Hospitals
      2. 10.3.2 Oncology Centers
      3. 10.3.3 Research Institutes
      4. 10.3.4 Specialty Clinics
      10.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.4.1 Germany
      2. 10.4.2 United Kingdom
      3. 10.4.3 France
      4. 10.4.4 Spain
      5. 10.4.5 Italy
      6. 10.4.6 Russia
      7. 10.4.7 Netherlands and Rest of Europe
    2. 10.5 Europe Global Checkpoint Inhibitors Market – Opportunity Analysis Index, By Drug Class, By Application, By End User, and Country, 2024 - 2031
    3. 10.6 Regional Trends Analysis
    4. 10.7 Europe Global Checkpoint Inhibitors Market Research Report - Company Profiles
      1. 10.7.1 Company 1 (Germany)
      2. 10.7.2 Company 2 (United Kingdom)
      3. 10.7.3 Company 3 (United Kingdom)
    11. Asia-Pacific Global Checkpoint Inhibitors Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 11.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.1.1 PD-1 Inhibitors
      2. 11.1.2 PD-L1 Inhibitors
      3. 11.1.3 CTLA-4 Inhibitors
      4. 11.1.4 Others (LAG-3, TIGIT, emerging targets)
      11.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.2.1 Lung Cancer
      2. 11.2.2 Melanoma
      3. 11.2.3 Renal Cell Carcinoma
      4. 11.2.4 Bladder Cancer
      5. 11.2.5 Head and Neck Cancer
      6. 11.2.6 Others (Triple-Negative Breast Cancer, Gastrointestinal Cancers)
      11.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.3.1 Hospitals
      2. 11.3.2 Oncology Centers
      3. 11.3.3 Research Institutes
      4. 11.3.4 Specialty Clinics
      11.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.4.1 China
      2. 11.4.2 Japan
      3. 11.4.3 India
      4. 11.4.4 South Korea
      5. 11.4.5 Australia & New Zealand
      6. 11.4.6 ASEAN
      7. 11.4.7 Rest of Asia-Pacific
    2. 11.5 Asia-Pacific Global Checkpoint Inhibitors Market – Opportunity Analysis Index, By Drug Class, By Application, By End User, and Country, 2024 - 2031
    3. 11.6 Regional Trends Analysis
    4. 11.7 Asia-Pacific Global Checkpoint Inhibitors Market Research Report - Company Profiles
      1. 11.7.1 Company 1 (China)
      2. 11.7.2 Company 2 (Japan)
      3. 11.7.3 Company 3 (Japan)
    12. Latin America Global Checkpoint Inhibitors Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 12.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.1.1 PD-1 Inhibitors
      2. 12.1.2 PD-L1 Inhibitors
      3. 12.1.3 CTLA-4 Inhibitors
      4. 12.1.4 Others (LAG-3, TIGIT, emerging targets)
      12.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.2.1 Lung Cancer
      2. 12.2.2 Melanoma
      3. 12.2.3 Renal Cell Carcinoma
      4. 12.2.4 Bladder Cancer
      5. 12.2.5 Head and Neck Cancer
      6. 12.2.6 Others (Triple-Negative Breast Cancer, Gastrointestinal Cancers)
      12.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.3.1 Hospitals
      2. 12.3.2 Oncology Centers
      3. 12.3.3 Research Institutes
      4. 12.3.4 Specialty Clinics
      12.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.4.1 Brazil
      2. 12.4.2 Mexico
      3. 12.4.3 Argentina
      4. 12.4.4 Peru
      5. 12.4.5 Colombia
      6. 12.4.6 Rest of Latin America
    2. 12.5 Latin America Global Checkpoint Inhibitors Market – Opportunity Analysis Index, By Drug Class, By Application, By End User, and Country, 2024 - 2031
    3. 12.6 Regional Trends Analysis
    4. 12.7 Latin America Global Checkpoint Inhibitors Market Research Report - Company Profiles
      1. 12.7.1 Company 1 (Brazil)
      2. 12.7.2 Company 2 (Mexico)
      3. 12.7.3 Company 3 (Mexico)
    13. Middle East and Africa Global Checkpoint Inhibitors Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 13.1 By Drug Class Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 13.1.1 PD-1 Inhibitors
      2. 13.1.2 PD-L1 Inhibitors
      3. 13.1.3 CTLA-4 Inhibitors
      4. 13.1.4 Others (LAG-3, TIGIT, emerging targets)
      13.2 By Application Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 13.2.1 Lung Cancer
      2. 13.2.2 Melanoma
      3. 13.2.3 Renal Cell Carcinoma
      4. 13.2.4 Bladder Cancer
      5. 13.2.5 Head and Neck Cancer
      6. 13.2.6 Others (Triple-Negative Breast Cancer, Gastrointestinal Cancers)
      13.3 By End User Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 13.3.1 Hospitals
      2. 13.3.2 Oncology Centers
      3. 13.3.3 Research Institutes
      4. 13.3.4 Specialty Clinics
      13.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 13.4.1 Saudi Arabia
      2. 13.4.2 UAE
      3. 13.4.3 Qatar
      4. 13.4.4 Egypt
      5. 13.4.5 Israel
      6. 13.4.6 Rest of Middle East and Africa
    2. 13.5 Middle East and Africa Global Checkpoint Inhibitors Market – Opportunity Analysis Index, By Drug Class, By Application, By End User, and Country, 2024 - 2031
    3. 13.6 Regional Trends Analysis
    4. 13.7 Middle East and Africa Global Checkpoint Inhibitors Market Research Report - Company Profiles
      1. 13.7.1 Company 1 (Saudi Arabia)
      2. 13.7.2 Company 2 (UAE)
      3. 13.7.3 Company 3 (UAE)
    14. Competition Landscape
    1. 14.1 Strategic Dashboard of Top Market Players
    2. 14.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
      1. 14.2.1 Bristol Myers Squibb
      2. 14.2.2 Merck & Co.
      3. 14.2.3 Roche
      4. 14.2.4 AstraZeneca
      5. 14.2.5 Pfizer
      6. 14.2.6 Novartis
      7. 14.2.7 Regeneron
      8. 14.2.8 Gilead Sciences
  1. 15. Data Collection Method and Research Approach
  2. 16. Principal Presumptions and Acronyms